Hospital
Aspirus Keweenaw
Aspirus Keweenaw was paid $6.03M by Medicaid between Jan 2018 and Dec 2024, across 135 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoASPIRUS KEWEENAW
LAURIUM, MI 49913
LAURIUM, MI 49913
33aNPI1326115569assigned 11/30/2006
33bProvider typeCritical Access Hospital
28Total paid$6.03M
24GClaims164,185
24DCodes billed135
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#15 of 31
Median peer was paid$6.03M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,828 | $619K | |
| 2019 | 24,549 | $571K | |
| 2020 | 20,086 | $731K | |
| 2021 | 23,397 | $1.03M | |
| 2022 | 24,188 | $1.03M | |
| 2023 | 25,594 | $1.11M | |
| 2024incomplete | 20,543 | $943K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 7,959 | 5,194 | $1.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 11,777 | 7,774 | $1.16M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 12% | 3,653 | 3,399 | $697K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.6% | 6,150 | 4,587 | $518K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.0% | 1,294 | 1,086 | $361K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 2,260 | 2,025 | $287K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.1% | 1,250 | 1,179 | $184K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 1,215 | 653 | $167K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 1,184 | 776 | $140K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,098 | 1,700 | $94K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 885 | 861 | $92K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 2,342 | 1,461 | $75K |
123 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,052 | $73K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 1,636 | $63K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,860 | $60K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,530 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 655 | $52K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,622 | $50K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,767 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,979 | $46K |
| 80053 | Comprehensive metabolic panel | <1% | 11,703 | $44K |
| 80061 | Lipid panel | <1% | 3,041 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,625 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,001 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,416 | $32K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 380 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,402 | $32K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,765 | $27K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 78 | $21K |
| 82728 | <1% | 2,290 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,409 | $18K |
| 73630 | <1% | 1,022 | $18K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 382 | $17K |
| 84439 | <1% | 3,111 | $17K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 781 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,958 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 169 | $10K |
| 86900 | <1% | 252 | $10K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 612 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 284 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 361 | $9K |
| 80306 | <1% | 1,737 | $8K | |
| 82607 | <1% | 865 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 382 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,673 | $7K |
| 87070 | <1% | 1,842 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 55 | $7K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 63 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 314 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,423 | $6K |
| 73564 | <1% | 177 | $6K | |
| 87088 | <1% | 1,193 | $5K | |
| 72100 | <1% | 155 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $4K |
| 73030 | <1% | 210 | $4K | |
| 73110 | <1% | 215 | $4K | |
| 86803 | <1% | 396 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,002 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 58 | $3K |
| 86665 | <1% | 179 | $3K | |
| 83735 | <1% | 2,682 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 134 | $3K |
| 73610 | <1% | 189 | $3K | |
| 86140 | <1% | 1,526 | $3K | |
| 73130 | <1% | 173 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,493 | $2K |
| 85610 | <1% | 2,001 | $2K | |
| 81001 | <1% | 3,802 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 88 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 67 | $2K |
| 76801 | <1% | 26 | $2K | |
| 84702 | <1% | 171 | $1K | |
| 86664 | <1% | 124 | $1K | |
| 87077 | <1% | 333 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 330 | $1K |
| 86850 | <1% | 372 | $1K | |
| 86663 | <1% | 124 | $1K | |
| 86376 | <1% | 130 | $1K | |
| 83690 | <1% | 1,394 | $933.22 | |
| 87186 | <1% | 225 | $892.50 | |
| 83540 | <1% | 197 | $811.20 | |
| 84481 | <1% | 90 | $804.06 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $640.86 |
| 85652 | <1% | 492 | $620.16 | |
| 83550 | <1% | 102 | $590.96 | |
| 82746 | <1% | 76 | $540.19 | |
| 88342 | <1% | 24 | $539.18 | |
| 85027 | <1% | 117 | $431.88 | |
| 84153 | <1% | 36 | $429.49 | |
| 94762 | <1% | 29 | $398.99 | |
| 86769 | <1% | 15 | $393.45 | |
| 73502 | <1% | 14 | $347.49 | |
| 84484 | <1% | 1,384 | $309.64 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 28 | $275.12 |
| 84425 | <1% | 24 | $237.62 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,073 | $235.06 |
| 86762 | <1% | 25 | $223.42 | |
| 81025 | <1% | 640 | $221.26 | |
| 83880 | <1% | 24 | $206.96 | |
| 85730 | <1% | 440 | $199.91 | |
| 86592 | <1% | 70 | $197.42 | |
| 86800 | <1% | 26 | $184.80 | |
| 82533 | <1% | 15 | $183.89 | |
| 87340 | <1% | 25 | $160.39 | |
| 83090 | <1% | 20 | $151.12 | |
| 82043 | <1% | 43 | $145.64 | |
| 87807 | <1% | 39 | $136.88 | |
| 82948 | <1% | 225 | $135.73 | |
| 87205 | <1% | 58 | $125.61 | |
| 85379 | <1% | 108 | $92.42 | |
| 82180 | <1% | 12 | $89.52 | |
| 83605 | <1% | 362 | $65.04 | |
| 84703 | <1% | 182 | $58.96 | |
| 82570 | <1% | 18 | $49.66 | |
| 82248 | <1% | 43 | $32.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 242 | $29.60 |
| 82550 | <1% | 14 | $5.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,275 | $3.88 |
| 94760 | 0% | 78 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,074 | $0.00 |
| 86901 | 0% | 262 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 978 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 153 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 27 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 40 | $0.00 |
| 82962 | 0% | 66 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 39 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 88 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 62 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,919 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,012 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 175 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 24 | $0.00 |
| 81291 | 0% | 12 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.